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Myostatin signals through miR-34a to regulate Fndc5
expression and browning of white adipocytes
X Ge1, D Sathiakumar1, BJG Lua2, H Kukreti2, M Lee1 and C McFarlane1
BACKGROUND/OBJECTIVES: Myostatin (Mstn) has a pivotal role in glucose and lipid metabolism. Mstn deficiency leads to the
increased browning of white adipose tissue (WAT), which results in the increased energy expenditure and protection against diet-
induced obesity and insulin resistance. In this study, we investigated the molecular mechanism(s) through which Mstn regulates
browning of white adipocytes.
METHODS: Quantitative molecular analyses were performed to assess Mstn regulation of miR-34a and Fndc5 expression. miR-34a
was overexpressed and repressed to investigate miR-34a regulation of Fndc5. Luciferase reporter analysis verified direct binding
between miR-34a and the Fndc5 3′-untranslated region (UTR). The browning phenotype of Mstn− /− adipocytes was assessed
through the analysis of brown fat marker gene expression, mitochondrial function and infrared thermography. The role of miR-34a
and Fndc5 in this browning phenotype was verified through antibody-mediated neutralization of FNDC5, knockdown of Fndc5 by
small interfering RNA and through miR-34a gain-of-function and loss-of-function experiments.
RESULTS: Mstn treatment of myoblasts inhibited Fndc5 expression, whereas the loss of Mstn increased Fndc5 levels in muscles and
in circulation. Mstn inhibition of Fndc5 is miR-34a dependent. Mstn treatment of C2C12 myoblasts upregulated miR-34a expression,
whereas reduced miR-34a expression was noted in Mstn− /− muscle and WAT. Subsequent overexpression of miR-34a inhibited
Fndc5 expression, whereas blockade of miR-34a increased Fndc5 expression in myoblasts. Reporter analysis revealed that miR-34a
directly suppresses Fndc5 expression through a miR-34a-specific binding site within the Fndc5 3′UTR. Importantly, Mstn-mediated
inhibition of Fndc5 was blocked upon miR-34a inhibition. Mstn− /− adipocytes showed reduced miR-34a, enhanced Fndc5 expression
and increased thermogenic gene expression, which was reversed upon either neutralization of Fndc5 or Fndc5 knockdown. In
agreement, Mstn− /− adipocytes have increased mitochondria, improved mitochondrial function and increased heat production.
CONCLUSIONS: Mstn regulates Fndc5/Irisin expression and secretion through a novel miR-34a-dependent post-transcriptional
mechanism. Loss of Mstn in mice leads to the increased Fndc5/Irisin expression, which contributes to the browning of white
adipocytes.
International Journal of Obesity (2017) 41, 137–148; doi:10.1038/ijo.2016.110
INTRODUCTION
The obesity epidemic represents a growing threat to health and
well-being worldwide, and is one of the major risk factors for the
development of cardiovascular disease, type 2 diabetes and
hypertension. The recent discovery of brown adipocytes in adult
humans1–3 has gained interest as a potential treatment for obesity.
Different from white adipocytes, classic brown adipocytes show a
multilocular lipid droplet phenotype and greater mitochondrial
density.4 Although white adipocytes store energy, brown adipo-
cytes burn energy through the production of heat by non-
shivering thermogenesis, thus playing an important role in
promoting total energy expenditure.5,6 Furthermore, brown
adipocytes have a unique gene expression profile, expressing
high levels of thermogenic genes such as uncoupling protein-1
(ucp1).6 In addition to brown adipose tissue (BAT), ‘brown-like’
adipocytes have been reported in white adipose tissue (WAT) and
have been termed beige adipocytes. These beige precursor cells
display a unique gene expression signature, different from both
classic brown and white adipocytes.7 However, in response to
various stimuli, beige precursor cells undergo trans-differentiation
and adopt a ‘brown-like’ thermogenic gene expression profile,
with robust ucp1 expression to promote thermogenesis.7 As
metabolically active cells, both brown and beige adipocytes could
facilitate weight loss and improve metabolic health.
Myostatin (Mstn), a well-studied negative regulator of skeletal
muscle growth and development,8–10 has also been shown to
inhibit fat mass accumulation11 and regulate glucose
homeostasis.12 Interestingly, loss of Mstn in mice increases energy
utilization and thus protects mice from either genetic or diet-
induced obesity.11,13–15 Consistent with this, WAT from Mstn− /−
mice has been shown to adopt a BAT-like phenotype with
associated induction of genes characteristic of brown/beige
adipocytes.11,16 Although we know that Mstn− /− WAT exhibits a
BAT-like phenotype, and that this may explain the increased
energy utilization observed in Mstn− /− mice, the underlying
molecular mechanism(s) have yet to be fully elucidated. However,
our previous publication has revealed enhanced cyclooxygenase-2
(COX-2) expression in Mstn− /− WAT.11 Given the fact that elevated
COX-2, and subsequent prostaglandin production/release, pro-
motes ucp1 expression in ingWAT,17,18 we hypothesized that
elevated COX-2 contributes to the increased expression of ucp1
and BAT-like phenotype in Mstn− /− mice.11 Recently, Shan et al.16
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revealed that inactivation of the Mstn gene in mice stimulates the
AMP-activated protein kinase signaling, which resulted in activa-
tion of the transcriptional co-activator PPAR-γ co-activator1-α.
Shan et al.16 further showed enhanced secretion of the PPAR-γ co-
activator1-α target, Irisin, into circulation in Mstn− /− mice, which
promoted BAT-like development in Mstn− /− WAT.
Irisin was initially described by Boström et al.19 and potently
induces ‘browning’ of WAT. Irisin is derived from the extracellular
N-terminal portion of the precursor protein, FNDC5 (fibronectin
type III domain containing 5). Irisin targets beige precursor cells in
WAT7 to promote the development of a BAT-like phenotype
potentially through improving the PPAR-α signaling, a nuclear
receptor driving ucp1 expression. Adenovirus-mediated over-
expression of Irisin in the liver protects mice from diet-induced
obesity and insulin resistance.19 Irisin is substantially upregulated
during endurance exercise in both mice and humans,19 as such
Irisin is believed to be an important mediator that links exercise
with associated health benefits. Moreover, given the role of Irisin
in promoting browning of WAT, Irisin may also be a promising
anti-obesity therapy.
Both Mstn and Irisin are myokines that are capable of
modulating lipid metabolism in fat tissue and controlling whole-
body energy expenditure. Evidence to date suggests that Irisin
and Mstn function to promote and inhibit the browning of WAT,
respectively; however, no work has been performed to assess
whether or not these two secreted factors converge to regulate
browning of WAT. Therefore, the main aim of this study was to
investigate the function of Mstn as a regulator of the brown
adipocyte-like thermogenic program in white adipocytes, and to
identify a potential link between Mstn and Irisin during this
process. In this study, we demonstrate that Mstn post-
transcriptionally inhibits Fndc5 expression via miR-34a in both
myoblasts and adipocytes. Mstn− /− adipocytes display increased
expression of brown adipocytes-specific marker genes, suggesting
that the loss of Mstn promotes the development of a brown
adipocyte-like phenotype in a cell-autonomous manner. Consis-
tent with the gene expression data, Mstn− /− white adipocytes
show increased mitochondria number and function, concomitant
with significantly increased heat production. Our results suggest
that the browning phenotype observed in Mstn− /− adipocytes can
be attributed to the decreased miR-34a expression and a
subsequent increase in the expression of Fndc5. In summary, we
propose that Mstn post-transcriptionally suppresses Fndc5 expres-
sion via a miR-34-dependent mechanism in both myoblasts and
white adipocytes.
MATERIALS AND METHODS
Animals
Wild-type (WT) male (C57BL/6J) mice were obtained from the Biological
Resource Centre, Singapore. Mstn− /+ mice were previously gifted from
Professor Se-Jin Lee (Johns Hopkins University, Baltimore, MD, USA). Mice
were maintained as previously described.12 Experiments were conducted
according to the Institutional Animal Care and Use Committee (Singapore)
approved protocols.
Cell culture
Primary stromal vascular fraction (SVF) cells from inguinal WAT (ingWAT) of
WT and Mstn− /− mice (7–9 weeks old) were isolated, maintained and
differentiated into mature adipocytes according to the published
protocol.20 Oil Red O (ORO) staining was used to detect cellular lipid
accumulation in mature adipocytes, as previously published.20 For
neutralization of endogenous Irisin in adipocytes, SVF cells isolated from
WT and Mstn− /− mice were differentiated in the presence of either
1.25 μg ml− 1 anti-Fndc5 antibody (ab131390, Abcam, Cambridge, UK),
which was raised against the C-terminal secreted portion of mouse FNDC5
(amino acids 50–150), or 1.25 μg ml− 1 rabbit IgG (X0903, Dako, Carpinteria,
CA, USA) as a negative control. For recombinant Mstn protein treatments,
WT and Mstn− /− SVF cells were differentiated in the presence of either
4.0 μg ml− 1 recombinant Mstn protein or dialysis buffer (negative control).
Expression and purification of recombinant Mstn protein from Escherichia
coli were conducted according to the previously published protocol.21 The
biological activity of the recombinant Mstn protein was assessed through
performing a C2C12 myoblast proliferation assay.22
Mouse C2C12 myoblasts were obtained from American Type Culture
Collection (Manassas, VA, USA) and maintained or differentiated into
myotubes as previously described.23 For Mstn protein treatment, C2C12
myoblasts were treated with 2.5, 3.0, 3.5 and 4.0 μg ml− 1 recombinant
Mstn protein for 24 h (dose-dependent treatment) or treated with
4.0 μg ml− 1 recombinant Mstn protein for 6, 12, 24 and 48 h (time-
dependent treatment). Control myoblasts were treated with an equal
volume of dialysis buffer.
Mouse primary myoblasts were isolated from hind-limb muscles of 4–6-
week-old male WT mice (C57BL/6), using the previously described
protocol.24 Primary myoblasts were seeded at the density of 15 000 cells
per cm2 and then treated with either 4.0 μg ml− 1 recombinant Mstn
protein or dialysis buffer for 24 h.
For all cell culture experiments, random wells were selected for
treatments. The parent C2C12 myoblasts stock was tested for mycoplasma.
Primary cultures were not tested for mycoplasma in this study.
Plasmids and recombinant adenovirus
The miR-34a overexpression plasmid was constructed by cloning 504 bp of
murine miR-34a (mmu-miR-34a) coding region between SpeI and SacII
restriction sites of the pEM157 vector (pMEV-miR-34a).
The 3′UTR region of the Fndc5 gene (~2000 bp) was amplified by PCR
and cloned into SpeI/HindIII sites of the pMIR-REPORT miRNA Expression
Luciferase Reporter Vector (Life Technologies, Grand Island, NY, USA; pMIR-
Fndc5 3′UTR). The putative miR-34a-binding site within the murine Fndc5
gene 3′UTR was mutated using a megaprimer PCR-based mutagenesis
approach, according to the published protocol.25 The mutated Fndc5 3′
UTR was then cloned into SpeI/HindIII sites of the pMIR-REPORT vector
(pMIR-Fndc5 3′UTR-mut).
The recombinant adenovirus used to overexpress miR-34a was
generated by subcloning the precursor mmu-miR-34a stem loop sequence
along with 100 bp of flanking upstream and downstream sequence,
Figure 1. Myostatin is a negative regulator of Fndc5/Irisin expression and secretion. (a) Fndc5 mRNA expression analysis (qPCR) in C2C12
myoblasts treated without (0 μg ml− 1) or with 2.5, 3.0, 3.5 or 4.0 μg ml− 1 recombinant Mstn protein for 24 h. Data show fold change (relative
to 0 μg ml− 1 control) ± s.e.m (n= 3 biological replicates) normalized to GAPDH expression. *Po0.05, ***Po0.001. (b) Fndc5 mRNA expression
analysis (qPCR) in C2C12 myoblasts treated without (control, dialysis buffer) or with 4.0 μg ml− 1 recombinant Mstn protein for 6, 12, 24 or 48 h.
Data show fold change (relative to respective control) ± s.e.m (n= 3 biological replicates) normalized to GAPDH expression. ***Po0.001.
(c) Fndc5 mRNA expression analysis (qPCR) in primary myoblasts isolated from WT mice treated without (control, dialysis buffer) or with
4.0 μg ml− 1 recombinant Mstn protein for 24 h. Data show fold change (relative to control) ± s.e.m (n= 3 biological replicates) normalized to
GAPDH expression. ***Po0.001. Fndc5 mRNA expression analysis (qPCR) in M. gastrocnemius muscle (Gas) (d) and M. Soleus muscle (Sol)
(e) muscles from WT and Mstn− /− mice. Data show fold change (relative to respective WT control) ± s.e.m (n= 6 mice per group) normalized
to GAPDH expression. **Po0.01, ***Po0.001. Immunoblot blot (IB) analysis of FNDC5 protein levels in Gas (f) and Sol (g) muscles from WT
and Mstn− /− mice. Graphs show densitometric analysis of FNDC5 protein levels in a.u.± s.e.m. (n= 3 mice per group for Gas IB; n= 3 WT mice
vs n= 5 Mstn− /− mice for Sol IB) normalized to GAPDH levels. *Po0.05. GAPDH levels were assessed in all IBs to ensure equal loading.
Irrelevant lanes loaded adjacent to the Mstn− /− lanes in the Gas IB have been removed. Only three representative lanes of WT and Mstn− /− are
shown in the Sol IB. (h) Enzyme-linked immunosorbent assay assessment of Irisin levels in serum collected from WT and Mstn− /− mice. Data
show mean± s.e.m. (n= 5 mice per group). ***Po0.001.
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as a BamhI/NheI fragment, into the pacAd5 miR-GFP/Puro Shuttle Vector
(Cell Biolabs, San Diego, CA, USA), according to the manufacturer’s
protocols. The Shuttle Vector containing mmu-miR-34a sequence and
pacAd5 9.2-100 Ad Backbone Vector was digested with PacI. After
purification, linearized Shuttle Vector containing the mmu-miR-34a
sequence and Backbone Vector were co-transfected into 293AD cells
(catalog no.: AD-100, Cell Biolabs) using Lipofectamine 2000 reagent
(Invitrogen, Carlsbad, CA, USA). Crude viral lysate was collected after
7 days incubation. Recombinant adenovirus, named pacAD5-miR-34a,
was collected from crude viral lysate with three freeze/thaw cycles.
Adenovirus that does not contain a miRNA fragment was used as a
negative control (pacAD5-neg).
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The sequences of all cloning and mutagenesis primers are provided in
Supplementary Information and all the constructs were sequence verified
before the use.
Transient transfection, transduction and establishment of stable
cell lines
For establishment of C2C12 myoblasts stably overexpressing miR-34a,
pMEV-miR-34a and control empty vector (pMEV-neg) were transfected
in C2C12 myoblasts using Lipofectamine 2000 reagent (Invitrogen),
according to the manufacturer’s instructions. Stably overexpressing
myoblasts were selected by continued neomycin (500 μg ml − 1) treat-
ment for a period of 20 days until resistant colonies became visible.
miR-34a-overexpressing clones were selected by quantitative PCR (qPCR)
analysis of miR-34a expression. To specifically inhibit miR-34a in C2C12
myoblasts, C2C12 myoblasts were transfected with either 200 nM
of AntagomiR-negative control (AntagomiR-neg) or miR-34a-specific
AntagomiR (AntagomiR-34a; Sigma, Singapore) using Lipofectamine
2000 reagent (Invitrogen). After 24-h transfection, C2C12 myoblasts were
treated with 4 μg ml − 1 recombinant Mstn protein for 24 h before RNA
sample collection. For transient overexpression of miR-34a in C2C12
myotubes, 72 h differentiated C2C12 myotubes were transduced with
either miR-34a-overexpressing adenovirus (pacAD5-miR-34a) or negative
control adenovirus (pacAD5-neg), at multiplicities of infection of 5, 10 and
20. Twenty-four hours post transduction, medium was replaced with fresh
medium and cells were allowed to grow for a further 24 h before RNA
collection. For transient overexpression of miR-34a in adipocytes, Mstn− /−
SVF cells were differentiated into white adipocytes for 8 days. Mstn− /−
white adipocytes were transduced with either pacAD5-miR-34a or pacAD5-
neg at multiplicities of infection of 50 for 48 h.
For transient inhibition of miR-34a in WT adipocytes, SVF cells isolated
from WT ingWAT were transfected with either 200 nM of AntagomiR-neg
or AntagomiR-34a (Sigma) by electroporation. Electroporation was under-
taken with a Bio-Rad Gene Pulser (Hercules, CA, USA) with a capacitance of
960 μF and a voltage of 220 V. Forty-eight hours after transfection, cells
were subjected to induction of white adipogenic differentiation for 8 days.
Fndc5 small interfering RNA transfection
Mstn− /− SVF cells were transfected with 0.05 μM mouse Fndc5 Accell
SMARTpool small interfering RNA (siRNA) mixture (siRNA-Fndc5), using
Accell siRNA Delivery Media, according to the manufacturer’s protocol
(Thermo Fisher Scientific, Waltham, MA, USA). Cells were cultured for 72 h
after transfection, then lysed for qPCR. Accell SMARTpool siRNA-Fndc5 is a
predesigned mixture of four individual Fndc5-targeting siRNAs, and siRNA-
control is a predesigned mixture of four individual non-targeting siRNAs.
The target sequences for the siRNA-Fndc5 and non-targeting Accell siRNA
Pool (siRNA-ctrl) are provided in Supplementary Information.
Luciferase assay
miR-34a-overexpressing C2C12 myoblasts and control myoblasts were
seeded onto 6-well-plates at a density of 15 000 cells per cm2 and allowed
to grow for 24 h before transfection. Proliferating C2C12 myoblasts were
transfected with 2 μg of pMIR-Fndc5 3′UTR or pMIR-Fndc5 3′UTR-mut
reporter plasmids per well, using Lipofectamine 2000 reagent (Invitrogen),
according to the manufacturer’s protocol. Twenty-four hours after
transfection, luciferase assay was conducted according to the previous
publication.23
RNA extraction and real-time qPCR
RNA extraction and qPCR were performed according to the previous
publication.12,23 Ct values of the target genes were normalized against Ct
values of housekeeping genes (GAPDH or Hsp90ab1) and the expression of
mature miR-34a was normalized to U6. Fold change was calculated using
the ΔΔCT method. The sequences of primers used in this study are
provided in Supplementary Information.
Western blot analysis
Protein preparation and western blotting were performed according to the
previous publication.12 Proteins were prepared from homogenized muscle
tissues using radioimmunoprecipitation assay buffer containing 1% IGEPAL
CA-630, 0.1% SDS, 0.5% sodium deoxycholate, 50 mM NaF, 1.5 mM NaVO4
and complete protease inhibitor (Roche, Nutley, NJ, USA). Proteins were
quantified using Bradford assay reagent (Bio-Rad) and equal amounts of
proteins were resolved using 4–12% gradient SDS-polyacrylamide gel
electrophoresis (Invitrogen) and transferred to a nitrocellulose membrane.
Deglycosylation was not performed for muscle protein extracts. Anti-
FNDC5 antibody (ab181884, Abcam), which targets C-terminal of FNDC5
protein, was used to detect FNDC5 full-length protein in muscle protein
extracts. Anti-GAPDH antibody (sc-32233, Santa Cruz, Biotechnology, Santa
Cruz, CA, USA) was used to detect GAPDH levels as a loading control.
Irisin enzyme-linked immunosorbent assay
Circulating Irisin levels were quantified using a commercial ELISA kit
(catalog no. EK-067-16; Phoenix Pharmaceuticals Inc., Burlingame, CA,
USA), as per the manufacturer’s protocol. Serum samples were diluted
1:100 in enzyme-linked immunosorbent assay buffer before quantification.
Irisin circulation levels were calculated by nonlinear regression using
GraphPad Prism 5 software (GraphPad Software, La Jolla, CA, USA).
Mitochondrial DNA per nuclear DNA ratio quantification
Relative mitochondrial DNA copy number (mtDNA) per nuclear DNA
(nuDNA) ratio in WT and Mstn− /− mature adipocytes was quantified by
qPCR analysis, as described previously.26 The sequence of primers used are
provided in Supplementary Information. Relative fold change of mtDNA
per nuDNA ratio was calculated using the ΔΔCT method.
Assessment of mitochondrial function
Mitochondrial function of WT and Mstn− /− mature adipocytes was
analyzed by measuring the oxygen consumption rate using an XFe24
Extracellular Flux Analyzer (Seahorse Bioscience, North Billerica, MA, USA),
according to the manufacturer’s instruction. In brief, following assessment
of basal respiration rate, protein leak and ATP turnover were measured in
Figure 2. miR-34a targets and represses Fndc5 expression. (a) Schematic highlighting 6mer and 7mer seed matches (gray boxes) between hsa-
miR-34a (same as mmu-miR-34a) and the miR-34a-binding site in mouse (mmu-Fndc5 3′UTR) and human (hsa-Fndc5 3′UTR) Fndc5 3′UTR,
respectively. Fndc5 (b) and miR-34a (c) expression analysis (qPCR) in control (transfected with pMEV-neg) or miR-34a-overexpressing C2C12
myoblasts (miR-34a OE; transfected with pMEV-miR-34a). Data show fold change (relative to control) ± s.e.m (n= 3 biological replicates)
normalized to either GAPDH (B) or U6 (c) expression. *Po0.05, ***Po0.001. Fndc5 (d) and miR-34a (e) expression analysis (qPCR) in C2C12
myoblasts transfected with control (AntagomiR-neg) or miR-34a-specific AntagomiR (AntagomiR-34a). Data show fold change (relative to
control) ± s.e.m (n= 3 biological replicates) normalized to either GAPDH (d) or U6 (e) expression. ***Po0.001. Fndc5 (f) and miR-34a
(g) expression analysis (qPCR) in 72 h differentiated C2C12 myotubes transduced with either negative control (pacAD5-neg) or miR-34a-
overexpressing (pacAD5-miR-34a) adenovirus at multiplicities of infection (MOI) of 5, 10 or 20 for 24 h. Data show fold change (relative to
respective controls) ± s.e.m (n= 3 biological replicates) normalized to either GAPDH (f) or U6 (g) expression. *Po0.05. (h) pMIR-REPORT
luciferase activity analysis in C2C12 myoblasts stably overexpressing miR-34a (pMEV-miR-34a) or control empty vector (pMEV-neg), transfected
with the Fndc5 3′UTR reporter construct (Fndc5 3′UTR) or the mutant Fndc5 3′UTR reporter construct (Fndc5 3′UTR-mut) with miR-34a-binding
site mutated. For pMIR-REPORT transfections, data represent fold change in firefly:Renilla luciferase activity ratio, relative to control myoblasts
transfected with the Fndc5 3′UTR reporter construct ± s.e.m (n= 3 biological replicates; experiment was repeated independently but data
given is from one representative experiment). ***Po0.001. Fndc5 (i) and miR-34a (j) expression analysis (qPCR) in M. gastrocnemius muscle
(Gas), M. tibialis anterior (TA), M. extensor digitorum longus (EDL) muscles, M. Soleus muscle (Sol), inguinal white adipose tissue (ingWAT),
retroperitoneal white adipose tissue (retroWAT) and brown adipose tissue (BAT) from WTmice. Data show fold change (relative to Gas) ± s.e.m
(n= 3 mice per group) normalized to either Hsp90ab1 (i) or U6 (j) expression. *Po0.05.
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the presence of oligomycin (4 μM) to inhibit ATP synthesis. Maximal
mitochondrial respiratory capacity was measured by adding carbonyl
cyanide-p-trifluoromethoxyphenylhydrazone (FCCP; 1.5 μM). Rotenone
(1 μM) and antimycin (1 μM) were added to assess non-mitochondrial
respiration.
Infrared thermography
WT and Mstn− /− SVF cells were seeded at the density of 10 000 cells per
cm2 in the center wells of 96-well-plates. Wells surrounding the plated SVF
wells contained 200 μl phosphate-buffered saline each. Mature adipocytes
were derived from SVF cells after white adipogenic differentiation, as
described above. Heat production from WT and Mstn− /− adipocytes
was measured by infrared thermography. Infrared thermography was
performed as previously described,27 with modifications. In brief, the
96-well-plates containing the cells were kept on a heating block
maintained at 35 °C within an insulating box. Images were captured using
an infrared camera (FLIR T420, Wilsonville, OR, USA) and then analyzed
using the FLIR Tools software (FLIR). Data were collected from triplicate
plates, five wells per genotype per plate.
Myostatin regulation of Fndc5 expression
X Ge et al
141
International Journal of Obesity (2017) 137 – 148
Statistical analysis
No specific test was performed to determine the sample size. Outliers were
determined using Z-scores. F-test was conducted to determine whether or
not variance was equal between sample groups. One-way analysis of
variance and two-tailed Student’s T-test were used for statistical analysis.
Significant levels were indicated; *Po0.05, **Po0.01 or ***Po0.001. Data
was expressed as mean± s.e.m. Investigators were not blinded during
allocation of experiment groups or during result analysis.
RESULTS
Mstn negatively regulates Fndc5/Irisin expression and secretion
Although loss of Mstn has been shown to increase Fndc5
expression in skeletal muscle and primary myotubes,16 no study
has to date assessed direct regulation of Fndc5 expression by
Mstn. Initially, we treated C2C12 myoblasts with recombinant
Mstn protein. Subsequent qPCR analysis revealed both a dose-
and time-dependent reduction in Fndc5 expression following
Mstn treatment (Figures 1a and b). Similarly, reduced Fndc5
expression was noted in murine primary myoblasts upon Mstn
treatment (Figure 1c). We next assessed Fndc5/Irisin expression
and secretion between WT and Mstn− /− mice. Interestingly, data
suggest that although Fndc5 messenger RNA (mRNA) expression
was decreased in both fast-twitch (Musculus gastrocnemius muscle,
Gas) and slow-twitch (Musculus soleus muscle, Sol) muscles from
Mstn− /− mice (Figures 1d–e), Fndc5 protein level was significantly
increased (Figures 1f–g). Consistent with this, enhanced circulat-
ing Irisin levels were also observed in Mstn− /− mice (Figure 1h).
Collectively, these data reveal that Mstn negatively regulates
Fndc5/Irisin expression and secretion.
miR-34a targets and represses Fndc5 expression through a
miR-34a-specific binding site in the Fndc5 3′UTR
Analysis using the TargetScan5.1 algorithm (http://www.targets
can.org/) revealed one target site for microRNA-34a (miR-34a) in
the 3′UTR region of both mouse and human Fndc5 (Figure 2a).
Consistent with this, Fndc5 expression was markedly down-
regulated in C2C12 myoblasts stably overexpressing miR-34a
(miR-34 OE; Figures 2b and c), when compared with empty vector
(control)-overexpressing myoblasts, whereas specific inhibition of
miR-34a through AntagomiR-34a transfection significantly
increased Fndc5 expression (Figures 2d and e). We further noted
a dose-dependent decrease in Fndc5 expression (Figure 2f) in 72 h
differentiated C2C12 myotubes transduced with increasing
amounts of miR-34a-overexpressing adenovirus (pacAD5-miR-34a;
Figure 2g). Moreover, a significant reduction in Fndc5 3′UTR
reporter activity was noted in miR-34a stable overexpressing
myoblasts (miR-34 OE), which was reversed upon mutation of the
miR-34a-binding site within the Fndc5 3′UTR (Figure 2h). We also
observed increased Fndc5 3′UTR reporter activity in myoblasts
transfected with Fndc5 3′UTR-mut, when compared with myo-
blasts transfected with WT Fndc5 3′UTR (Figure 2h). Taken
together, these data suggest that miR-34a represses Fndc5 gene
expression, and that the miR-34a-binding site in the Fndc5 3′UTR
is required.
We next assessed the role of miR-34a in regulating tissue-
specific Fndc5 expression by measuring both miR-34a and Fndc5
expression in different tissues. Fndc5 expression was detectable in
all muscles and adipose tissues tested; however, highest Fndc5
expression was noted in skeletal muscle (Figure 2i). This finding is
in agreement with the previous studies that show Irisin is
predominantly produced and secreted from skeletal
muscle.19,28,29 Consistent with the increased Fndc5 expression,
skeletal muscles had the lowest miR-34a expression when
compared with WAT and BAT (Figure 2j). These data strongly
support that Fndc5 and miR-34a expression is inversely associated
between different tissues, suggesting that miR-34a regulates
Fndc5 tissue-specific expression.
Mstn downregulates Fndc5 expression via a miR-34a-dependent
mechanism
As both Mstn and miR-34a negatively regulate Fndc5
expression, we next investigated miR-34a involvement in
Mstn regulation of Fndc5 expression. Mature miR-34a expression
was significantly increased in a dose- and time-dependent
manner upon Mstn treatment (Figures 3a and b) in C2C12
myoblasts. Consistent with this, miR-34a expression was signifi-
cantly reduced in both Gas muscle and ingWAT from Mstn− /−
mice (Figures 3c and d). Importantly, AntagomiR-mediated
inhibition of miR-34a (AntagomiR-34a) in C2C12 myoblasts led
to increased expression of Fndc5 over and above endogenous
levels and also prevented Mstn-mediated inhibition of Fndc5
(Figure 3e). Taken together, these data suggest that Mstn
inhibition of Fndc5 is miR-34a dependent.
Loss of Mstn drives browning of white adipocytes in vitro through
miR-34a regulation of Fndc5 expression
As we observed reduced expression of miR-34a in ingWAT isolated
from Mstn− /− mice (Figure 3d), we next assessed the expression of
Fndc5 and miR-34a in differentiated white adipocytes derived
from WT and Mstn− /− SVF cells. Although Oil Red O staining
revealed similar lipid accumulation during adipogenic differentia-
tion between adipocytes derived from WT and Mstn− /− SVF cells
(Figure 4a); significantly reduced miR-34a expression, concomitant
with the increased Fndc5 expression, was observed in Mstn− /−
mature white adipocytes (Figures 4b and c). Consistent with this,
significantly increased expression of several BAT marker genes,
including ucp1, cox7a1, ebf3, hsph7 and cidea, was noted in
Mstn− /− mature white adipocytes, when compared with WT
adipocytes (Figure 4d). Conversely, the expression of genes
characteristic of white adipocytes, such as lep (leptin) and adipoq
(adiponectin), was repressed in Mstn− /− mature white adipocytes
(Figure 4d). These data suggest that the loss of Mstn in mature
adipocytes leads to the reduced miR-34a expression, increased
expression of Fndc5 and activation of brown adipocyte-specific
marker genes.
As Mstn− /− mature white adipocytes displayed increased brown
adipocyte gene expression, we further investigated the effects of
Mstn inactivation in mature adipocytes on mitochondrial number
and function. We observed an increase in the mtDNA copy
number to nuDNA copy number (mtDNA:nuDNA) ratio in Mstn− /−
mature white adipocytes (Figure 4e). Analysis of adipocyte
bioenergetic profiles using an XFe24 extracellular flux analyzer
(Seahorse Bioscience) demonstrated that basal mitochondrial
respiration, OCR due to proton leak and maximal mitochondrial
respiratory capacity were increased in Mstn− /− mature adipocytes
(Figure 4f). Consistent with the increased thermogenic gene
expression, infrared thermography revealed a significant increase
in heat production in Mstn− /− mature adipocytes, which suggests
enhanced thermogenic capacity (Figure 4g). Taken together, these
data indicate that the loss of Mstn promotes induction of a
‘browning’ program in mature white adipocytes, which was
evidenced through upregulation of brown adipocytes-specific
genes, increased mitochondria number, improved mitochondrial
activity and greater thermogenic capacity.
Next, we assessed whether or not the browning phenotype
noted in Mstn− /− mature adipocytes was due to the increased
expression of Fndc5/Irisin. As such, we neutralized Irisin in the
culture medium of Mstn− /− and WT SVF cells during in vitro
adipogenic differentiation using an Fndc5-specific antibody and
assessed lipid droplet accumulation through Oil Red O staining
and the expression of BAT and WAT marker genes in SVF-derived
mature adipocytes. No significant difference in lipid accumulation
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was noted between WT and Mstn− /− mature adipocytes treated
with either control IgG or anti-Fndc5-specific antibody (Figure 5a).
However, a significant reduction in expression of BAT marker
genes (ucp1, cox7a1, ebf3, hsph7 and cidea) and increased
expression of WAT marker genes (lep and ap2) were observed in
Mstn− /− mature adipocytes upon antibody-mediated neutraliza-
tion of Fndc5 (Figure 5b). We further knocked down endogenous
Fndc5 expression (Figure 5c) in Mstn− /− SVF cells by transfecting
cells with small interfering RNA (siRNA) targeting mouse Fndc5
mRNA (siRNA-Fndc5). Subsequent analysis revealed reduced ucp1
expression in siRNA-Fndc5-transfected SVF cells, compared with
SVF cells transfected with control non-targeting siRNA (siRNA-ctrl;
Figure 5d). These data reveal that Fndc5/Irisin contributes, at least
in part, to the increased expression of ucp1 observed in Mstn− /−
adipocytes/SVF cells.
Given the above results, we hypothesized that Mstn represses
Fndc5 expression via miR-34a in adipocytes. Consistent with this
hypothesis, Mstn treatment of WT SVF cells during in vitro
adipogenic differentiation resulted in a significantly increased
miR-34a expression (Figure 5e), concomitant with the reduced
Fndc5 expression (Figure 5f), which was also associated with the
decreased expression of several WAT (lep and adipoq) and BAT
marker genes (ucp1, cox7a1 and cidea; Figure 5g). A similar
decrease in ucp1, cox7a1 and cidea was noted in Mstn-treated
Mstn− /− SVF cells during in vitro adipogenic differentiation.
However, increased expression of the BAT marker genes, ebf3
and hsph7, was noted upon Mstn treatment in WT mature
adipocytes. In addition, inhibition of miR-34a expression in WT
mature adipocytes by AntagomiR-34a (Figure 5h) led to enhanced
Fndc5 (Figure 5i) and ucp1 expression (Figure 5j). Furthermore,
adenoviral-mediated overexpression of miR-34a in Mstn− /−
mature adipocytes (Figure 5k) led to the decreased Fndc5
(Figure 5l) and ucp1 expression (Figure 5m). These results indicate
that Mstn has a role in the browning of white adipocytes through
regulating endogenous Fndc5 expression through a miR-34a-
dependent mechanism.
DISCUSSION
Our previously published results revealed that the loss of Mstn in
mice increases total energy expenditure and protects against
high-fat diet-induced obesity and insulin resistance.11 Although
we know that enhanced browning of WAT in Mstn− /− mice was, at
least in part, responsible for the increased energy expenditure and
resistance to high-fat diet-induced obesity observed, the under-
lying molecular mechanism(s) behind this phenomenon remained
to be fully understood. In 2012, Irisin was discovered as a key
exercise-induced myokine that promotes browning of WAT and
increased energy expenditure.19 Recently, Shan et al.16 revealed
that the loss of Mstn promotes increased Fndc5/Irisin expression,
through the activating AMP-activated protein kinase–PPAR-γ co-
activator1-α signaling, suggesting that the browning phenotype
observed in Mstn− /− mice may be due to elevated Irisin. We have
now described a novel miR-34a-dependent post-transcriptional
Figure 3. Mstn inhibits Fndc5 gene expression via a miR-34a-dependent mechanism. (a) Mature miR-34a expression analysis (qPCR) in C2C12
myoblasts treated without (0 μg ml− 1) or with 2.5, 3.0, 3.5 or 4.0 μg ml− 1 recombinant Mstn protein for 24 h. Data show fold change (relative
to 0 μg ml− 1 control) ± s.e.m (n= 3 biological replicates) normalized to U6 expression. *Po0.05, ***Po0.001. (b) Mature miR-34a expression
analysis (qPCR) in C2C12 myoblasts treated without (control, dialysis buffer) or with 4.0 μg ml− 1 recombinant Mstn protein for 6, 12, 24 or 48 h.
Data show fold change (relative to respective Control) ± s.e.m (n= 3 biological replicates) normalized to U6 expression. ***Po0.001. Mature
miR-34a expression analysis (qPCR) in Gas muscle (c) and ingWAT (d) collected from WT and Mstn− /− mice. Data show fold change (relative to
WT Control) ± s.e.m (n= 5 mice per group) normalized to U6 expression. **Po0.01, ***Po0.001. (e) Fndc5 mRNA expression analysis (qPCR) in
C2C12 myoblasts transfected with either negative control AntagomiR (AntagomiR-neg) or miR-34a-specific AntagomiR (AntagomiR-34a) for
24 h, followed by a further 24 h in the absence (control, dialysis buffer) or presence of 4.0 μg ml− 1 recombinant Mstn protein (Mstn). Data
show fold change (relative to AntagomiR-neg) ± s.e.m (n= 3 biological replicates) normalized to GAPDH expression. ***Po0.001.
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Figure 4. Loss of Mstn promotes the browning of white adipocytes. (a) Oil Red O (ORO) staining of stromal vascular fraction (SVF)-derived
adipocytes from WT and Mstn− /− mice. Graph displays quantification of ORO staining (OD 520 nm). miR-34a (b) and Fndc5 (c) expression
analysis (qPCR) in WT and Mstn− /− adipocytes. Data show fold change (relative to respective WT control) ± s.e.m (n= 3 biological replicates;
experiment was repeated independently, but the data given are from one representative experiment) normalized to U6 (b) or GAPDH (c)
expression. **Po0.01. (d) BAT (cox7a1, ebf3, hspb7, ucp1, cidea and prdm16) and WAT (lep and adipoq) marker gene expression analysis (qPCR)
in WT and Mstn− /− adipocytes. Data show fold change (relative to respective WT control) ± s.e.m (n= 3 biological replicates; experiment was
repeated independently, but the data given are from one representative experiment) normalized to GAPDH expression. *Po0.05, **Po0.01,
***Po0.001. (e) mtDNA:nuDNA ratio (qPCR) in WT and Mstn− /− white adipocytes. Data show fold change (relative to respective WT control)
± s.e.m (n= 3 biological replicates). *Po0.05. (f) Left: oxygen consumption rate (ORC) measured by XFe24 extracellular flux analyzer (Seahorse
Bioscience) in WT and Mstn− /− adipocytes at basal and after sequential injection of oligomycin (Oligo), cyanide-p-trifluoromethoxyphenylhy-
drazone (FCCP) and antimycin+rotenone (A/R). Right: graph showing basal OCR, OCR resulting from proton leak (H+ leak), ATP-linked OCR and
maximal OCR in adipocytes from WT and Mstn− /− mice. Data show OCR normalized against total protein concentration ± s.e.m (n= 4
biological replicates; experiment was repeated independently, but the data given are from one representative experiment). **Po0.01,
***Po0.001. (g) Infrared thermographic images of WT and Mstn− /− adipocytes. Color representation of the temperature scale is given. Graph
displays quantification of heat production in WT and Mstn− /− adipocytes. Data show mean temperature ± s.e.m (n= 3 biological replicates;
experiment was repeated independently, but the data given are from one representative experiment). *Po0.05.
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Figure 5. Mstn regulation of Fndc5 expression and browning in white adipocytes is miR-34a dependent. (a) Representative images of Oil Red
O (ORO) staining of WT and Mstn− /− mature adipocytes treated with either rabbit IgG (control IgG) or with anti-Fndc5-specific antibody (Fndc5
Ab). Scale bar= 100 μm. Graph displays quantification of ORO staining (OD 520 nm). (b) BAT (cox7a1, ebf3, hspb7, ucp1, cidea and prdm16) and
WAT (lep, adipoq and ap2) marker gene expression analysis (qPCR) in WT and Mstn− /− adipocytes treated with rabbit IgG (control) or with
Fndc5-neutralizing antibody (Fndc5 Ab). Data show fold change (relative to control) ± s.e.m (n= 3 biological replicates; experiment was
repeated independently, but the data given are from one representative experiment) normalized to GAPDH expression. *Po0.05, **Po0.01.
Fndc5 (c) and ucp1 (d) mRNA expression analysis (qPCR) in Mstn− /− SVF cells transfected with either 0.05 μM of Fndc5-specific siRNA pool
(siRNA-Fndc5) or with 0.05 μM of non-targeting siRNA pool (siRNA-ctrl) for 72 h. Data show fold change (relative to respective control) ± s.e.m
(n= 3 biological replicates) normalized to GAPDH expression. *Po0.05. miR-34a (e), Fndc5 (f), BAT (cox7a1, ebf3, hspb7, ucp1, cidea and prdm16)
and WAT (lep, adipoq and ap2) (g) marker gene expression analysis (qPCR) in WT and/or Mstn / adipocytes treated without (control, dialysis
buffer) or with 4.0 μg ml− 1 recombinant Mstn protein (Mstn). Data show fold change (relative to respective control) ± s.e.m (n= 3 biological
replicates) normalized to U6 (e) or GAPDH (f, g) expression. *Po0.05, **Po0.01. Mature miR-34a (h), Fndc5 (i) and ucp1 (j) expression analysis
(qPCR) in differentiated white adipocytes from WT SVF cells transfected with either negative control AntagomiR (AntagomiR-neg) or miR-34a-
specific AntagomiR (AntagomiR-34a). Data show fold change (relative to AntagomiR-neg) ± s.e.m (n= 3 biological replicates) normalized to U6
(h) or GAPDH (i, j) expression. *Po0.05, ***Po0.001. Mature miR-34a (k), Fndc5 (l) and ucp1 (m) expression analysis (qPCR) in Mstn− /−
differentiated SVF-derived white adipocytes after transduction with either negative control adenovirus (pacAD5-neg) or miR-34a-
overexpressing adenovirus (pacAD5-miR-34a) at multiplicities of infection (MOI) of 50 for 48 h. Data show fold change (relative to pacAD5-
neg) ± s.e.m (n= 3 biological replicates) normalized to either U6 (k) or GAPDH (l and m) expression. *Po0.05, **Po0.01.
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mechanism through which Mstn regulates Fndc5/Irisin and thus
browning of white adipocytes. Moreover, we now show that the
absence of Mstn promotes browning of white adipocytes through
autocrine regulation of endogenous Fndc5/Irisin expression in
white adipocytes. Interestingly, in contrast to results presented by
Shan et al.,16 we find the decreased Fndc5 mRNA expression,
together with the increased Fndc5 protein level in skeletal
muscles of Mstn− /− mice (Figures 1d–g). This result suggests the
existence of a potential negative autoregulatory feedback loop,
where the elevated Fndc5/Irisin protein levels found in muscle
and in circulation, in turn inhibits Fndc5 expression. However, as
we observed the increased Fndc5 mRNA expression in ingWAT of
Mstn− /− mice, compared with WAT from WT mice (data not
shown), this negative autoregulatory mechanism may be skeletal
muscle tissue specific. However, further work will need to be
undertaken to verify the existence of an Irisin negative
autoregulatory feedback loop and the potential role that this
has in regulation of Irisin function.
Although we have shown that Mstn upregulates miR-34a, the
molecular mechanism(s) behind this regulation remains to be
elucidated. However, unpublished data from our lab suggests that
Mstn may transcriptionally regulate miR-34a expression, as we
observed the increased expression of both precursor and mature
miR-34a upon exogenous Mstn treatment in C2C12 myoblasts
(data not shown). Nonetheless, we cannot rule out the possibility
that Mstn may also regulate miR-34a processing; as such further
work is required to clarify this.
It is important to highlight that the above data were generated
using mice and murine cell culture model systems. As such, further
work should be undertaken to investigate the role of Mstn and
miR-34a in regulating Fndc5 expression in humans. This is
underscored by the findings of a recent publication that
confirmed, through mass spectrometry, the existence of full-
length circulating Irisin protein in humans.30 Both Mstn and Irisin
proteins are remarkably well conserved across species, with 100%
identical amino-acid sequence of mature Mstn and Irisin proteins
between mouse and human.19,31 Together with the fact that
human and mouse miR-34a sequences are identical (Figure 2a), it
is quite possible that the same regulatory mechanism outlined
here exists in humans. Consistent with this, higher Mstn secretion
has been observed in obese patients,32 whereas the decreased
Mstn expression was noted in skeletal muscle after weight loss
due to biliopancreatic diversion.33 In addition, higher expression
of miR-34a was found in adipocytes from obese individuals 34 and
in the liver of type 2 diabetes patients.33 In addition, research also
suggests that Irisin levels are significantly reduced in obese35,36
and type 2 diabetes patients.37–39 Taken together, these
correlative data suggest that Mstn may also regulate Fndc5
expression in humans through miR-34a; however, further work will
need to be performed to validate this.
Recent published evidence suggests a role for miR-34a in
regulating browning of WAT.40,41 Fu et al. has revealed that
miR-34a inhibits the browning transcriptional program in all types
of WAT through interfering with fibroblast growth factor 21
(FGF21) signaling.40,41 Inhibition of miR-34a in adipose tissues or
adipocytes improved FGF21 sensitivity, whereas overexpression of
miR-34a reversed cold-exposure-induced browning phenotype in
3T3-L1 adipocytes.40 FGF21 robustly induces a BAT-like phenotype
in WAT through the activating PPAR-γ co-activator1-α–UCP1
signaling42 and is considered as a potential target for the
treatment of obesity-related diseases such as diabetes.43 Similar
to FGF21, Irisin is another potent ‘browning agent’19 and as we
have shown here the Irisin precursor gene Fndc5 is also targeted
by miR-34a. These data suggest that miR-34a is a general inhibitor
of WAT browning, through interfering with the signaling of at least
two key regulators of browning, FGF21 and Irisin. Future studies
using miR-34a gain-of-function or loss-of-function mouse models
will help us to further clarify the role of miR-34a in regulating Irisin
level, as well as the impact of this regulation on systemic glucose
and lipid metabolism in multiple tissues.
In contrast to the study by Shan et al.,16 we find a substantial
difference between WT and Mstn− /− adipocytes with respect to
gene expression and function. Compared with WT adipocytes, we
observed that Mstn− /− adipocytes display upregulated thermo-
genic gene expression (Figure 4d), greater mitochondria number
(Figure 4e), enhanced mitochondrial function (Figure 4f) and a
significant, albeit modest, increase in heat production (Figure 4g).
Therefore, contrary to the results presented by Shan et al., we
hypothesize that the loss of Mstn in white adipocytes results in
cell-autonomous browning due to both reduced miR-34a expres-
sion (Figure 4b) and increased Fndc5 expression (Figure 4c) in
Mstn− /− adipocytes. In agreement with this, Roca-Rivada et al.29
have previously demonstrated that WAT expresses and secretes
Fndc5, and further suggest that Irisin can act on white adipocytes
Figure 6. Mstn modulates post-transcriptional expression of Fndc5 via a miR-34a-dependent mechanism. Elevated Mstn levels results in
interaction of Mstn with its cell surface receptors and subsequent activation of Mstn downstream signaling. Activated Mstn signaling
promotes increased expression of miR-34a, which subsequently targets and inhibits Fndc5 mRNA. We propose that the loss of Mstn signaling
results in both decreased miR-34a expression and enhanced Fndc5 expression and Irisin secretion, contributing at least in part to the
pronounced browning phenotype observed in Mstn− /− WAT.
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not only in an endocrine manner but also through an autocrine
pathway. In addition, we further show that both antibody-
mediated neutralization of Irisin in Mstn− /− white adipocytes is
able to significantly decrease the elevated expression of ucp1 and
additional BAT marker genes (cox7a1, ebf3, hspb7 and cidea)
observed in Mstn− /− adipocytes when compared with control
(Figure 5b). A similar reduction in ucp1 expression was noted upon
siRNA-mediated inhibition of Fndc5 expression in Mstn− /−
adipocytes (Figures 5c and d). However, it is noteworthy to
mention that antibody-mediated neutralization of Irisin was not
able to completely reduce the increased ucp1 expression in
Mstn− /− adipocytes, to the same level in WT adipocytes
(Figure 5b). We therefore speculate that additional factors, other
than Irisin may contribute to the enhanced browning and
thermogenic gene expression observed in Mstn− /− white adipo-
cytes. As FGF21 signaling is also targeted by miR-34a, and given
the reduced miR-34a expression in Mstn− /− adipocytes
(Figure 4b), it is likely that enhanced FGF21 signaling may also
promote browning of Mstn− /− adipocytes. However, further
studies will need to be performed to assess the expression of
other miR-34 targets including FGF21 receptor components in
Mstn− /− adipocytes. In addition to FGF21, we have previously
shown that the loss of Mstn promotes the browning of WAT
through a mechanism involving COX-2.11 Given the fact that
COX-2 can promote the expression of ucp1 and induce browning
of WAT,17 it is quite possible that enhanced COX-2 expression may
also contribute to the elevated ucp1 expression observed in
Mstn− /− adipocytes.
Mstn was initially characterized as a potent inhibitor of skeletal
muscle growth and development.8–10 However, in recent years, its
role in the regulation of insulin signaling, glucose and lipid
metabolism has gained attention.11–15 It is well accepted that
inhibition of Mstn signaling improves insulin sensitivity and
prevents obesity. However, there is controversy as to whether
these beneficial effects are secondary to an improved metabolic
phenotype in skeletal muscle, or whether Mstn acts as a direct
regulator of glucose and lipid metabolism in other tissues. Our
study strongly suggests that Mstn can function as a direct
regulator of metabolic phenotype in tissues other than skeletal
muscle. Most certainly, treatment of white adipocytes with
exogenous Mstn resulted in the reduced expression of Fndc5
and BAT marker genes (Figures 5e and f). Moreover, loss of Mstn
signaling in white adipocytes promoted the development of a
brown adipose tissue-like phenotype through enhancing endo-
genous white adipocyte Fndc5 expression (Figures 4c and d-g).
Guo et al.14 have shown that tissue-specific inhibition of Mstn
signaling in skeletal muscle, rather than in adipose tissue, led to
the reduced adipose tissue mass and improved insulin sensitivity.
Through adipose-specific expression of dominant negative activin
type IIB receptor (ActRIIB), Guo et al. blocked Mstn signaling in
adipocytes and demonstrated no decrease fat mass and no
metabolic benefits in mice. However, this study cannot exclude
the direct role of Mstn in regulating adipocytes, as Mstn has also
been shown to activate downstream signaling through binding to
the activin type IIA receptor,44 although Mstn binds to ActRIIB with
higher affinity. Therefore, without complete blockade of Mstn
signaling it would be difficult to rule out a direct role for Mstn in
adipocyte metabolism.
In summary, here we have described a novel miR-34a-
dependent signaling mechanism through which Mstn inhibits
Fndc5 expression (Figure 6). We further propose that the loss of
Mstn results in decreased miR-34a expression, which promotes
increased Fndc5/Irisin expression and secretion. Enhanced Irisin
levels in turn drives thermogenic gene expression and the brown
adipocyte-like phenotype in Mstn− /− white adipocytes. To our
knowledge, this is the first study to identify a microRNA-
dependent post-transcriptional mechanism through which Mstn
regulates metabolic function.
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